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Abstract
Pandemic (H1N1) 2009 virus-positive specimens were collected
from autopsy patients and matched to pandemic (H1N1) 2009
virus-positive nasopharyngeal specimens from community con-
trol patients and pandemic (H1N1) 2009 virus-positive speci-
mens from intensive-care unit (ICU) patients. Specimens were
analysed for polymorphisms at amino acid 222 of the haemagglu-
tinin (HA) glycoprotein. Whereas some specimens from autopsy
patients were positive for D222N, none was positive for
D222G. All control patient specimens were wild-type D222.
D222G polymorphisms were also identiﬁed in a subset of ICU
patients with admixtures of D222G and D222 and of D222N,
D222G and D222 present. The relevance of D222N and D222G
to inﬂuenza pathogenesis and transmissibility currently remains
unclear.
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The inﬂuenza pandemic of 2009–2010 saw the emergence of
a virus that caused mild disease in most patients. In some
cases, especially among patients with underlying risk factors,
inﬂuenza infection was associated with severe and sometimes
fatal outcomes [1]. During the 2009–2010 inﬂuenza pan-
demic, there were sporadic reports of pandemic (H1N1)
2009 virus that harboured replacements of the wild-type
aspartic acid by other amino acids at position 222 of the
haemagglutinin (HA) glycoprotein (http://www.who.int/csr/
resources/publications/swineﬂu/cp165_2009_2812_review_
d222g_amino_acid_substitution_in_ha_h1n1_viruses.pdf). Some
studies have found an association between severe clinical
outcomes and the presence of the aspartic acid ﬁ glycine
substitution at amino acid position 222 (D222G) in HA [2,3],
and descriptions of HA mutations in necropsy patients have
included mutations in HA 301–316 and HA 219–240 [4]. As
a limited number of studies have examined the D222G sub-
stitution in both mild and fatal cases, it is unclear whether
D222G is associated with increased disease severity, pro-
gression and spread of viral infection to the lower respira-
tory tract (LRT).
The purpose of this brief study was to identify the pres-
ence of D222 polymorphisms in HA from autopsy cases in
Alberta, Canada, and to determine whether these amino acid
substitutions were associated with fatality.
Selected specimens submitted to the Provincial Laboratory
for Public Health between June and November 2009 for
inﬂuenza A virus testing were included in this study.
Sample-speciﬁc data were acquired from a web-based tool
developed in collaboration with Canadian Public Health Intel-
ligence that has case-based tool data generated from aggre-
gate specimens maintained by the Provincial Laboratory for
Public Health. Mortality data for patients infected with the
pandemic (H1N1) 2009 virus recorded by Alberta Health
and Wellness were entered into the web-based database and
used to conﬁrm mortality outcome for cases and controls in
this study. A laboratory database was used to track control
patients for further specimens originating in an intensive-care
unit (ICU). Available autopsy tissue and respiratory speci-
mens from deceased patients were matched to control cases
by age, gender, pandemic wave and geographical location.
Control cases were patients who: (i) had a nasopharyngeal
(NP) swab result that was positive for the pandemic (H1N1)
2009 virus; (ii) were known not to have a fatal outcome; and
(iii) had no record of any specimens submitted from an ICU.
Only autopsy cases that could be matched to at least one
control patient were included in the study.
An additional group of ICU patients were also included in
this study. These ICU patients were matched to autopsy
cases by age, gender, pandemic wave and geographical loca-
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tion. Individuals included in the ICU patient group were non-
deceased during the study time period.
The algorithm for detection of the pandemic (H1N1)
2009 virus was used as previously described [5]. Analysis of
the HA gene sequence from primary clinical specimens was
carried out according to the WHO protocol (http://
www.who.int/csr/resources/publications/swineﬂu/sequenc-
ing_primers/en/index.html), with an emphasis on detection of
amino acid substitutions at position 222. Data were collected
with ABI software v2.0 in a 3130 Genetic analyzer (Applied
Biosystems, Foster City, CA, USA). HA nucleotide sequence
data were analysed with Sequencing Analysis Software v5.3
(Applied Biosystems). Sequence alignments were performed
with ClustalW v1.4 included in BioEdit v7.0.0 (http://
www.mbio.ncsu.edu/BioEdit/bioedit.html), and sequences
were compared with published pandemic H1N1 (2009) virus
sequences available from GenBank to study changes in the
HA gene.
Statistical analysis was carried out with Graphpad
Prism 5.1 (GraphPad Software, La Jolla, CA, USA).
Eleven specimens were obtained from ﬁve deceased
patients (including antemortem specimens and at autopsy),
and these results are given in Table 1. As shown in Table 1,
an inﬂuenza A virus with a D222N substitution was detected
in a right upper lung autopsy sample in case 1. An admixture
of viruses with D22 and D222N was identiﬁed in endotra-
cheal tube (ETT) specimens in case 5 prior to death. Case 5
also had a D222N specimen identiﬁed from the left bronchus
at autopsy. In contrast, six NP specimens from ﬁve control
patients positive for pandemic (H1N1) 2009 virus were anal-
ysed. All pandemic (H1N1) 2009 viruses from control
patients hadD222.
Apart from the control group, an additional nine speci-
mens from ﬁve ICU patients were also analysed for polymor-
phisms at position 222 of HA (Table 2). In this group, one
patient matched autopsy case 1, one patient matched
autopsy case 2 and three patients matched autopsy case 5
for geographical location, gender, pandemic wave and age.
The bronchoalveolar lavage (BAL) ﬂuid from ICU patient 1
(case match 1) contained a wild-type D22virus. An ETT aspi-
rate and NP swab from ICU patient 2 (case match 2) both
contained an admixture of D222N, D222G and D222. The
ICU patients matching case 5 are referred to as ICU
patients 5a, 5b and 5c. For ICU patient 5a, one NP specimen
contained wild type D222, and an NP specimen collected
later contained an admixture of D222G and D222; one ETT
sample had an admixture of D222G and D222. For
patient 5b, both BAL specimen and an NP specimen con-
tained the wild-type D222 virus. For patient 5c, a BAL speci-
men also contained wild-type D222 virus.
All specimens from all patients (deceased, ICU and con-
trols) were combined in order to compare the prevalence of
polymorphisms (N/G) at position 222 between NP and LRT
sites. It should be noted that there was a trend for greater
percentages of polymorphisms in LRT specimens (5/11, 45%)
than in NP specimens (2/14, 14%) (Fisher’s exact test,
p 0.18).
Several studies have described HA mutations in pandemic
inﬂuenza viruses, and some have found associations with
poor outcomes of patients [2,3,6]. From this study, it is clear
that polymorphisms at position 222 of HA were not neces-
sary for a fatal outcome. The polymorphisms described at
position 222 of HA in autopsy cases are D222N and an
admixture of D222N and D222. In ICU patients, D222N and
admixtures of D222N, D222G and D222 and of D222G and
D222 were detected. Although the relevance of these poly-
morphisms is still unknown, it should be noted that these
polymorphisms were identiﬁed in primary clinical isolates
and not in viral cultures, indicating that they are not muta-
tions occurring in viral culture [7].
The D222G mutations that were identiﬁed in this study
were not found in autopsy cases, or in community controls,
TABLE 1. D222 polymorphisms in haemagglutinin of pan-
demic (H1N1) 2009 viruses from autopsy cases
Case no.
Time of
sampling Specimen type
Amino acid at
position 222
1 Antemortem NP D
Autopsy Right upper lung BX N
2 Antemortem NP D
Autopsy Lung BX No band
3 Autopsy NP D
Autopsy Left lung BX D
4 Autopsy NP D
Autopsy Left lung BX D
5 Antemortem ETT D/N
Autopsy Tracheal BX D
Autopsy Left bronchus N
BX, biopsy; ETT, endotracheal tube; NP, nasopharyngeal swab..
TABLE 2. D222 polymorphisms in haemagglutinin of pan-
demic (H1N1) 2009 viruses from intensive-care unit
patients
Patient no.
Specimen
type
Amino acid at
position 222
1 BAL D
2 ETT D/N/G
NP D/N/G
5a NP D
NP D/G
ETT D/G
5b NP D
BAL D
5c BAL D
BAL, bronchoalveolar lavage; ETT, endotracheal tube; NP, nasopharyngeal swab.
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but were detected in some matched ICU patients. Further-
more, the polymorphisms were not exclusively D222G, but
mixed D222N, D222G and D222, a trend that has been pre-
viously reported http://ecdc.europa.eu/en/activities/sciadvice/
Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f%
2D77d4%2D4ad8%2Db6d6%2Dbf0f23083f30&ID=695).
It is noteworthy that the amino acid 222 falls within the
220-loop region of the receptor-binding domain of HA [8],
and that mutations in this domain are linked to the switch in
afﬁnity from the a-2,3-sialic acid (SA) receptor (favoured by
avian inﬂuenza viruses) to the a-2,6-SA receptor (favoured
by human inﬂuenza viruses) [9,10].
The location of SA in the human respiratory tract has been
the subject of earlier studies. Whereas the epithelial cells of
the human upper respiratory tract harbour almost exclusively
a-2,6-SA, a population of cells in the LRT, identiﬁed as type II
pneumocytes, also contain a-2,3-SA. This localization of a-2,3-
SA in the LRT is thought to account for the LRT infection
caused by avian inﬂuenza A (H5N1) viruses in humans [10].
Using glycan microarray analysis, Stevens et al. [9] have
shown that for the inﬂuenza A (H1N1) 1918 pandemic virus,
simultaneous E187D and G222D mutations must occur for
the receptor afﬁnity to switch from a-2,3-SA to a-2,6-SA.
This ﬁnding was corroborated by Tumpey et al. [11]. It is of
note that inﬂuenza strain A/New York/1/18 (H1N1), isolated
early in the 1918 pandemic (and therefore possibly a transi-
tional strain), harboured D187 and D222G and displayed
dual (but reduced) afﬁnity for a-2,3-SA and a-2,6-SA. As the
current pandemic (H1N1) 2009 viruses have been shown to
have D187 [12], the D222G substitution might be postulated
to reverse the binding phenotype to that of a dual-binding
virus, possibly allowing the virus to take advantage of the
a-2,3-SA present in some cells in the LRT.
It is noteworthy that Childs et al. [13] reported that early
isolates of the pandemic (H1N1) 2009 virus have a mixed a-
2,3-SA/a-2,6-SA speciﬁcity. However, Yang et al. [12], perhaps
because of the different methodology, reported that the pan-
demic (H1N1) 2009 virus has a strict preference for a-2,6-SA.
Furthermore, when Yang et al. studied the effects of the
D222G and D222N mutations on the receptor afﬁnity of the
pandemic (H1N1) 2009 virus, they found that, in contrast to
the effects on inﬂuenza A (H1N1) 1918 strains, these muta-
tions did not alter binding to a-2,6-SA. However, it should be
noted that weak binding to a-2,3-SA was also observed.
Therefore, Yang et al. concluded that these mutations have a
much less dramatic effect on HA of the pandemic (H1N1)
2009 virus than on HA of the inﬂuenza A (H1N1) 1918 virus.
In conclusion, the milder impact of D222 substitutions on
HA of the pandemic (H1N1) 2009 virus may explain why
admixtures are encountered without clear correlations with
pathogenicity. However, further studies will be needed to
completely elucidate this point.
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